Join to View Full Profile
277 George StNew Brunswick, NJ 08901
Phone+1 732-235-6700
Dr. Marcella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Bridgeport Hospital/Yale UniversityResidency, Pediatrics, 1984 - 1987
Albany Medical CenterInternship, Internal Medicine, 1983 - 1984
New York University School of MedicineClass of 1983
Certifications & Licensure
NJ State Medical License 1995 - 2025
PA State Medical License 1987 - 1996
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer Start of enrollment: 2003 Jun 01
Publications & Presentations
PubMed
- 31 citationsReal-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.Richard L Hengel, Timothy E. Ritter, Ramesh V Nathan, Lucinda J. Van Anglen, Claudia P. Schroeder
Open Forum Infectious Diseases. 2020-03-19 - 6 citationsIncidence of and risk factors for recurrent Clostridioides difficile infection in Japan using a claims database: A retrospective cohort studyHiroshige Mikamo, Takayuki Kondo, Kotoba Okuyama, Stephen Marcella, Daniel J. Ruzicka
Anaerobe. 2020-02-01 - 6 citationsBezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.Anirban Basu, Vimalanand S. Prabhu, Mary Beth Dorr, Yoav Golan, Erik R. Dubberke
Open Forum Infectious Diseases. 2018-11-01
Journal Articles
- Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium Difficile InfectionStephen Marcella, Yoav Golan, Clinical Infectious Diseases
Press Mentions
Novel Siderophore Cephalosporin Nets Promising Results in Tough-to-Treat CRABOctober 23rd, 2022- Shionogi to Present in Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (Cefiderocol) Against Gram-Negative PathogensSeptember 29th, 2021
Significant Costs Linked to Hospital-Acquired C. DifficileJuly 29th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
